01 50ASTRAZENECA AB
01 66515117
02 67919598
03 27951400
04 28221786
05 48361972
06 88501698
07 98628799
08 68716251
09 39339472
10 49616028
01 12Y
02 38Blank
01 40Y
02 10Blank
01 122025-07-13
02 62025-10-04
03 82027-06-20
04 122028-03-21
05 22028-11-30
06 62029-12-16
07 42030-11-12
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2028-03-21
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8361972
Drug Substance Claim :
Drug Product Claim :
Application Number : 209091
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2028-03-21
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2025-10-04
DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 6515117
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 210874
Patent Use Code : U-493
Delist Requested :
Patent Use Description : TREATMENT OF TYPE 2 DI...
Patent Expiration Date : 2025-10-04
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1976
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
Patent Expiration Date : 2027-06-20
DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE
US Patent Number : 8501698
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 209091
Patent Use Code : U-1977
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2027-06-20
LOOKING FOR A SUPPLIER?
